Maven Securities LTD Takes $1.79 Million Position in Humacyte, Inc. $HUMA

Key Points

• Maven Securities LTD has acquired 1,049,828 shares of Humacyte, Inc., valued at approximately $1.79 million, representing about 0.68% ownership in the company.
• Humacyte reported a loss per share of ($0.24), missing the consensus estimate, while the company generated revenue of $0.30 million for the quarter.
• Analyst ratings for Humacyte vary, with prices targets ranging from $3.00 to $25.00, and an average rating of "Moderate Buy" according to MarketBeat.com.

Maven Securities LTD acquired a new position in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,049,828 shares of the company's stock, valued at approximately $1,790,000. Maven Securities LTD owned 0.68% of Humacyte at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of Humacyte by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock worth $10,785,000 after acquiring an additional 94,915 shares during the period. Wells Fargo & Company MN increased its holdings in Humacyte by 40.9% during the fourth quarter. Wells Fargo & Company MN now owns 50,454 shares of the company's stock valued at $255,000 after buying an additional 14,649 shares during the period. Legal & General Group Plc increased its holdings in Humacyte by 19.5% during the fourth quarter. Legal & General Group Plc now owns 81,405 shares of the company's stock valued at $411,000 after buying an additional 13,293 shares during the period. Raymond James Financial Inc. purchased a new position in Humacyte during the fourth quarter valued at approximately $377,000. Finally, Rockefeller Capital Management L.P. purchased a new position in Humacyte during the fourth quarter valued at approximately $251,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Trading Down 5.5%

Shares of NASDAQ:HUMA traded down $0.09 during trading on Thursday, reaching $1.54. The stock had a trading volume of 4,904,132 shares, compared to its average volume of 6,243,794. The business has a fifty day moving average price of $2.24 and a 200-day moving average price of $2.38. The company has a quick ratio of 1.93, a current ratio of 2.45 and a debt-to-equity ratio of 2.97. The stock has a market cap of $238.88 million, a P/E ratio of -3.42 and a beta of 1.90. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $7.48.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The firm had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.94 million. As a group, analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Insider Transactions at Humacyte

In other news, CEO Laura E. Niklason sold 591,685 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total value of $934,862.30. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 591,685 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total transaction of $934,862.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,482,090 shares of company stock worth $7,466,382. Company insiders own 5.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Benchmark lowered their price objective on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. HC Wainwright decreased their price target on Humacyte from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Wall Street Zen cut shares of Humacyte from a "hold" rating to a "sell" rating in a research report on Sunday. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research report on Monday, August 11th. Finally, TD Cowen reduced their price objective on shares of Humacyte from $5.00 to $3.50 and set a "buy" rating on the stock in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Humacyte currently has an average rating of "Buy" and an average target price of $10.64.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.